Peptide · Fact sheet
Semaglutide
Also known as Ozempic · Wegovy · Rybelsus
Semaglutide is the active ingredient in several FDA-approved prescription medicines. Approval is product- and use-specific; it does not make every semaglutide product or every claimed use approved.
What is Semaglutide?
Semaglutide is a manufactured peptide-like medicine that acts on the GLP-1 receptor, part of a signaling system involved in blood sugar, appetite, and digestion.
The active ingredient appears in different prescription products. Those products are not interchangeable in every context, and their FDA labels differ.
Benefits people look for
People commonly search for semaglutide because of its established roles in type 2 diabetes care and chronic weight management.
Researchers also study cardiovascular, kidney, liver, and other outcomes. A study result does not automatically create a new approved use.
What the evidence supports
- Randomized trials show clinically meaningful benefits for the uses and populations described in approved labels.
- Ongoing studies are asking whether benefits extend to additional conditions; those questions should remain separate from established indications.
All research areas
- Type 2 diabetes
- Chronic weight management
- Cardiovascular outcomes
- Kidney outcomes
- Metabolic liver disease
- Additional outcomes beyond the exact product label and population
- Uses outside the population or indication of a particular FDA-approved label
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
Less intense hunger, with nausea
A person describing their first week with Ozempic reported calmer hunger and some nausea after meals.
Selected public self-report; identity, product contents, other exposures and outcomes were not independently verified. It cannot establish causation or frequency.
Read the first-week report ↗Weight loss without quieter food thoughts
Another person reported no change in persistent food thoughts after two months, despite nausea that made eating difficult and accompanying weight loss.
The product formulation and medical history are unclear. Weight loss alone does not show improved wellbeing; this is one unverified account.
Read the contrasting report ↗Side effects & risks
- Common gastrointestinal effects can include nausea, vomiting, diarrhea, constipation, and abdominal discomfort.
- Current labels contain important warnings and contraindications, including a boxed warning about thyroid C-cell tumors observed in rodents.
- Other labeled concerns can include pancreatitis, gallbladder disease, kidney injury related to dehydration, and low blood sugar when combined with certain diabetes medicines.
- Compounded products are not FDA-approved and do not undergo the same premarket review for safety, effectiveness, and quality.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesMultiple large randomized trials support approved uses. Evidence for a specific goal must still be matched to the product, population, outcome, and current label.
Selected research to read
Registry record for the SELECT semaglutide cardiovascular outcomes trial.
Peer-reviewed report of a large semaglutide cardiovascular outcomes trial.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| SELECT Age 45+, established cardiovascular disease, BMI ≥27, no diabetes 17,604 participants (actual) Randomized placebo-controlled trial; human | Semaglutide versus Placebo Mean follow-up 39.8 months Primary: First cardiovascular death, nonfatal heart attack or nonfatal stroke Phase: Not listed in this summary | 569/8803 (6.5%) versus 701/8801 (8.0%) had a primary event. 1.5 percentage points fewer events, using rounded published proportions. Hazard ratio 0.80; 95% CI 0.72–0.90. A hazard ratio is not a risk ratio. Cannot tell us: A secondary-prevention population; not a trial in healthy adults or a head-to-head comparison. Safety, uncertainty, and source detailsDiscontinuation due to adverse events: 16.6% versus 8.2%. Limited to the studied population, formulation and follow-up. Funding/conflicts: Funded by Novo Nordisk; individual disclosures not fully extracted. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
What did SELECT establish about cardiovascular events?
Fewer composite cardiovascular events than placebo in the studied high-risk population.
Limit: Does not establish benefit in every population or rank active medicines.
Check the sources: SELECT: cardiovascular outcomes without diabetes (checked 2026-09-18) · Wegovy prescribing information (DailyMed) (checked 2026-09-18)
Do Wegovy tablets and injection have identical indications?
The label separates formulations, ages and the injection-only MASH indication.
Limit: An ingredient-level approval cannot be assigned to all formulations or indications.
Check the sources: Wegovy prescribing information (DailyMed) (checked 2026-09-18)
What is approved, and for whom?
United States records selected for the questions above; not a complete label or a worldwide approval inventory.
Wegovy: Weight management
Subcutaneous injection · Adults with obesity or overweight plus a weight-related condition; ages 12+ with obesity
approved — Adjunct to reduced-calorie diet and increased physical activity. This is label scope, not a recommendation.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Wegovy: Weight management
Oral tablet · Adults with obesity or overweight plus a weight-related condition
approved — Do not transfer pediatric injection scope to tablets.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Wegovy: MASH
Subcutaneous injection · Adults with noncirrhotic MASH and fibrosis consistent with F2–F3
accelerated approval — Based on MASH and fibrosis improvement; continued approval may depend on confirmatory clinical benefit.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Wegovy: MASH
Oral tablet · MASH population
not in label — The reviewed label assigns this indication to injection, not tablets. Absence from this label is not a global regulatory search.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Wegovy: Cardiovascular outcomes
Subcutaneous injection · Adults with established cardiovascular disease and overweight or obesity
approved — Risk reduction for cardiovascular death, nonfatal myocardial infarction or nonfatal stroke.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Compare research questions · Submit a source-based correction
FDA approval & research status
Semaglutide approvals are product-specific. Wegovy injection and tablets have distinct population scopes. Wegovy injection also has an accelerated-approval indication for adults with noncirrhotic MASH and F2–F3 fibrosis; that indication is not assigned to tablets in the reviewed label. Other products have their own diabetes, kidney or cardiovascular label scope.
Approved uses covered here
- Improving blood sugar control in specified people with type 2 diabetes
- Chronic weight management in specified people with obesity or overweight
- Reducing specified cardiovascular risks in certain labeled populations
- Wegovy injection: noncirrhotic MASH with F2–F3 fibrosis in adults, under accelerated approval
FDA approved for product-specific uses
Product labels separate diabetes, weight, cardiovascular and other indications. Wegovy injection has an accelerated-approval MASH indication in a defined adult population; the reviewed label does not assign that indication to tablets.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- How every benefit-risk tradeoff changes across individual medical histories
- Whether ongoing trials will support additional labeled indications
- Very long-term outcomes for additional uses and broader populations
- The safety, quality, and equivalence of unapproved products marketed as semaglutide
The takeaway
Semaglutide has substantial human evidence and legitimate approved uses. The careful question is not simply whether semaglutide is approved, but which product, for whom, and for what exact use.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Wegovy
Official semaglutide prescribing information for a chronic-weight-management product.
- 2fdaFDA prescribing information: Ozempic
Official semaglutide prescribing information for a type 2 diabetes product.
- 3fdaFDA: Wegovy cardiovascular risk-reduction approval
FDA announcement describing the approved indication and supporting evidence.
- 4clinical trialsClinicalTrials.gov: SELECT cardiovascular outcomes trial
Registry record for the SELECT semaglutide cardiovascular outcomes trial.
- 5pubmedSELECT cardiovascular outcomes trial
Peer-reviewed report of a large semaglutide cardiovascular outcomes trial.